Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Investing Activities: 2021-2024

Historic Cash from Investing Activities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Dec 2024 value amounting to $31.3 million.

  • Centessa Pharmaceuticals' Cash from Investing Activities rose 37.77% to $61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.4 million, marking a year-over-year decrease of 1360.67%. This contributed to the annual value of $31.3 million for FY2024, which is 124.62% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Cash from Investing Activities of $31.3 million as of FY2024, which was up 124.62% from -$127.0 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Cash from Investing Activities ranged from a high of $63.3 million in FY2021 and a low of -$127.0 million during FY2023.
  • In the last 3 years, Centessa Pharmaceuticals' Cash from Investing Activities had a median value of -$931,000 in 2022 and averaged -$32.2 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Cash from Investing Activities plummeted by 13,541.68% in 2023, and later spiked by 124.62% in 2024.
  • Centessa Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $63.3 million in 2021, then tumbled by 101.47% to -$931,000 in 2022, then slumped by 13,541.68% to -$127.0 million in 2023, then soared by 124.62% to $31.3 million in 2024.